UK Markets close in 2 hrs 26 mins

Zealand Pharma A/S – Transaction Under Share Repurchase Program

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Company announcement – No. 47 / 2021

Zealand Pharma A/S – Transaction Under Share Repurchase Program

Copenhagen, DK and Boston, MA, 20 July 2021 - On June 29, 2021, Zealand Pharma A/S ("Zealand") initiated a share repurchase program to acquire Danish common stock for incentive programs in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016.

Zealand has entered an arrangement with Danske Bank A/S to act as exclusive manager under the program. Danske Bank A/S will buy back shares on behalf of Zealand and make related trading decisions independently of and without influence by Zealand.

Under the program, Danske Bank A/S will buy back shares on behalf of Zealand for an amount up to DKK 32,070,896. The share repurchase program is expected to be completed no later than July 29, 2021 and comprises up to 154,187 shares.

Since the announcement dated 6 July 2021, the following transactions have been made:

Number of shares

Average price
(DKK)

Total value
(DKK)

Accumulated, last announcement

85,000

187.41

15,929,550

13 July 2021

10,000

184,68

1.846,000

14 July 2021

10,000

183,37

1,833,700

15 July 2021

10,000

180,30

1,803,000

16 July 2021

9,065

181,86

1,648,561

19 July 2021

10,000

182,56

1,825,600

Total

49,065

182,56

8,956,861

Accumulated under the program

134,065

185,64

24,886,411


The details for each transaction made under the share repurchase program are included as an appendix to this announcement.

With the transactions stated above, Zealand owns a total of 198,288 shares with a nominal value of DKK 1 each as treasury shares, corresponding to 0.46% of the total share capital. The total share capital of the company is DKK 43,541,838 with a nominal value of DKK 1 each.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development. In the United States Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes and Zegalogue® for the treatment of severe hypoglycemia in pediatric patients with diabetes aged 6 years and above. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

V-go® and Zegalouge® are registered trademarks of Zealand Pharma A/S

Forward-Looking Statement

The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For further information, please contact:

Zealand Pharma Investor Relations

Claudia Styslinger

Argot Partners

investors@zealandpharma.com


Zealand Pharma Media Relations

David Rosen

Argot Partners

media@zealandpharma.com



Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting